Revolution Medicines on Saturday presented updated data to bolster the case for its lead cancer drug — designed to stop tumor growth by throttling back mutations in a common cell-signaling pathway.
The drug, called RMC-4630, won’t shrink tumors very much on its own. The drug’s main purpose will be as a backbone of combination treatments. The first test of this pairing strategy will come toward the end of the year, when Amgen reads out results of a study using RMC-4630 to boost the efficacy of sotorasib, its mutant KRAS-blocking lung cancer drug.
On Saturday, Revolution said updated data from an early-stage study showed RMC-4630, administered on its own, induced two partial responses from 40 patients with lung cancer containing mutated KRAS protein. But another 21 patients had stable disease, meaning their tumors stopped growing, although didn’t shrink enough to be classified as a response.